Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/7/2017
SIETES contiene 91906 citas

 
 
 1 a 20 de 6729 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Hodges NL, Spiller HA, Casavant MJ, Chounthirath T, Smith GA. Non-health care facility medication errors resulting in serious medical outcomes. Clinical Toxicology 2017:1-8. [Ref.ID 101917]
3. Cita con resumen
Anónimo. FDA approves guselkumab for treatment of plaque psoriasis. DIA Daily 2017:2. [Ref.ID 101909]
4. Cita con resumen
Patorno E, Glynn RJ, Levin R, Lee MP, Huybrechts KF. Benzodiazepines and risk of all cause mortality in adults: cohort study. BMJ 2017;358:j2941. [Ref.ID 101907]
5. Cita con resumen
Guy Jr GP, Zhang K, Bohm MK, Lewis B, Young R, Murphy LB, Dowell D. Vital Signs: changes in opioid prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep 2017;66:697-704. [Ref.ID 101665]
6. Cita con resumen
Xu J, Emenanjo O, Ortwerth M, Lurie P. Association of appearance of conflicts of interest with voting behavior at FDA advisory committee meetings—A cross-sectional study. JAMA Intern Med 2017;177:1038-40. [Ref.ID 101664]
7. Cita con resumen
8. Cita con resumen
Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open 2017;7:e015735. [Ref.ID 101661]
9. Cita con resumen
Anónimo. FDA announces list of off-patent drugs with no competition. DIA Daily 2017:1. [Ref.ID 101658]
10. Cita con resumen
Armstrong D. Kentucky Senate president urges release of secret OxyContin records. STAT 2017:1. [Ref.ID 101657]
11. Cita con resumen
Waljee AK, Rogers MAM, Lin P, Singal AG, Stein JD, Marks RM, Ayanian JZ, Nallamothu BK. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ 2017;357:j1415. [Ref.ID 101633]
12. Cita con resumen
Kesselheim AS, Donneyong M, Dal Pan GJ, Zhou EH, Avorn J, Schneeweiss S, Seeger JD. Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. Pharmacoepidemiol Drug Saf 2017;26:712-21. [Ref.ID 101627]
13. Cita con resumen
Poudel DR, Acharya P, Ghimire S, Dhital R, Bharati R. Burden of hospitalizations related to adverse drug events in the USA: a retrospective analysis from large inpatient database. Pharmacoepidemiol Drug Saf 2017;26:635-41. [Ref.ID 101626]
14. Cita con resumen
Becker WC, Fiellin DA. Abuse-deterrent opioid formulations - Putting the potential benefits into perspective. N Engl J Med 2017;376:2103-5. [Ref.ID 101625]
15. Cita con resumen
Anónimo. Pfizer increases US list prices of 91 drugs by average of 20 percent. DIA Daily 2017:1. [Ref.ID 101624]
16. Cita con resumen
Tsai W-C, Wu H-Y, Peng Y-S, Yang J-Y, Chen HY, Chiu Y-L, Hsu S-P, Ko M-J, Pai M-F, Tu Y-K, Hung K-Y, Chien K-L. Association of a communication training program with use of antipsychotics in nursing homes. JAMA Intern Med 2017;177:846-53. [Ref.ID 101620]
19. Cita con resumen
20. Cita con resumen
Pease AM, Krumholz HM, Hines HH, Downing NS, Aminawung JA, Shah ND, Ross JS. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ 2017;357:j1680. [Ref.ID 101573]
Seleccionar todas
 
 1 a 20 de 6729 siguiente >>